Share chart Adverum Biotechnologies, Inc.
Extended chart
Simple chart
About Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc., компания на клинической стадии, разрабатывает кандидаты на продукты генной терапии для лечения глазных и редких заболеваний. Его ведущим кандидатом на продукт является иксобероген соропарвовек (ADVM-022), кандидат для генной терапии с однократной интравитреальной инъекцией, используемый для лечения пациентов с хронической сетчаткой, включая влажную возрастную дегенерацию желтого пятна и диабетический отек желтого пятна. Компания разрабатывает ADVM-062 (AAV. more detailsMain settings
| IPO date | 2014-07-31 |
|---|---|
| ISIN | US00773U1088 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | link |
| Change price per day: | 0% (2.27) |
|---|---|
| Change price per week: | 0% (2.27) |
| Change price per month: | -21.18% (2.88) |
| Change price per 3 month: | -45.69% (4.18) |
| Change price per half year: | -64.81% (6.45) |
| Change price per year: | -71.7% (8.02) |
| Change price per 3 year: | +159.76% (0.8739) |
| Change price per 5 year: | -83.47% (13.73) |
| Change price per year to date: | -52.11% (4.74) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 92.38 | 1 |
| P/BV | 1.31 | 9 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -74.21 | 0 |
| ROE, % | -169.83 | 0 |
| ROIC, % | 0 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.6768 | 10 |
| Debt/Ratio | 0.5099 | 9 |
| Debt/Equity | 1.54 | 7 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | -86.67 | 0 |
| Yield Ebitda, % | 19.08 | 3 |
| Yield EPS, % | 379.58 | 10 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| FMR, LLC | 7 769 824 | 7.73 |
| Morgan Stanley | 6 964 642 | 6.92 |
| Bank of America Corporation | 5 591 790 | 5.56 |
| Bml Capital Management, LLC | 5 157 179 | 5.13 |
| Versant Venture Management, LLC | 5 068 233 | 5.04 |
| COMMODORE CAPITAL LP | 5 000 000 | 4.97 |
| Goldman Sachs Group Inc | 4 557 659 | 4.53 |
| Vanguard Group Inc | 4 143 131 | 4.12 |
| Blackrock Inc. | 2 037 550 | 2.03 |
| Sonic Gp LLC | 2 000 000 | 1.99 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Laurent Fischer | President, CEO & Director | 1.02M | 1964 (61 year) |
| Ms. Linda M. Rubinstein M.A. | CFO, Principal Financial Officer & Principal Accounting Officer | 940.99k | 1967 (58 years) |
| Mr. Kishor Peter Soparkar J.D. | Chief Operating Officer | 674.98k | 1971 (54 years) |
| Mr. John W. Rakow J.D. | Senior VP & General Counsel | 954.24k | 1957 (68 years) |
| Dr. Setareh Seyedkazemi Pharm.D. | Chief Development Officer | 656.84k | 1974 (51 year) |
| Dr. R. Andrew Ramelmeier Ph.D. | Chief Technology Officer | N/A | 1962 (63 years) |
| Ms. Dena House | Chief People Officer | N/A | |
| Ms. Carla Fiankan | Senior Vice President of Regulatory Affairs | N/A | |
| Dr. Romuald Corbau Ph.D. | Chief Scientific Officer | N/A | 1969 (56 years) |
| Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer | 1968 (57 years) |
About company
Address: United States, Redwood City. CA, 100 Cardinal Way - Open in google maps, Open in yandex maps
Website: https://adverum.com
Website: https://adverum.com
